Loading stock data…
$403.95+2.58 (+0.64%)
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
Natera, Inc. in the Healthcare sector is trading at $403.95 with a market capitalization of $44.7B. Wall Street consensus targets $411.39 (22 analysts), implying a +1.8% move over the next 12 months. The stock is currently near its 52-week high of $437.41, remaining 54.4% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $752.75M↑ | $696.64M↑ | $665.50M↑ | $592.18M↑ | $546.60M |
| Gross Profit | $485.19M↑ | $450.83M↑ | $445.43M↑ | $384.38M↑ | $346.60M |
| Operating Income | -$75.79M↑ | -$93.52M↓ | -$22.79M↑ | -$97.58M↑ | -$110.37M |
| Net Income | -$66.97M↑ | -$85.09M↓ | $47.26M↑ | -$87.54M↑ | -$100.94M |
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of tre...